 OncoSec Medical Incorporated OncoSec Nasdaq: ONCS, a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of data showing that TAVOTM plasmid-based interleukin-12 treatment, administered through OncoSecs electroporation gene delivery system, resulted in regression of injected and non-injected Merkel cell carcinoma MCC tumors. The study, a pilot with fifteen patients, is featured on the cover of the February issue of Clinical Cancer Research print edition available here. 